Latent Multi-drug Resistant Tuberculosis: An Unaddressed Problem
<p>It is estimated that three of every 1,000 individuals worldwide have latent Multidrug-Resistant Tuberculosis (MDR-TB) infection. Management of latent MDR-TB is an integral component in our strategies targeting global TB elimination. We are currently targeting only latent drug-sensitive TB a...
Gorde:
| Egile Nagusiak: | , |
|---|---|
| Formatua: | Liburua |
| Argitaratua: |
Archives of Pulmonology and Respiratory Care - Peertechz Publications,
2020-11-25.
|
| Gaiak: | |
| Sarrera elektronikoa: | Connect to this object online. |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
| Gaia: | <p>It is estimated that three of every 1,000 individuals worldwide have latent Multidrug-Resistant Tuberculosis (MDR-TB) infection. Management of latent MDR-TB is an integral component in our strategies targeting global TB elimination. We are currently targeting only latent drug-sensitive TB as there are no consensus guidelines on the management of latent MDR-TB. Such an approach can potentially lead to a "fall and rise phenomenon" in latent MDR-TB. Risk factors for latent MDR-TB need to be identified, and high-risk individuals need to be screened and treated on priority for latent MDR-TB. The treatment of latent MDR-TB can be initiated primarily with fluoroquinolones-based treatment regimes. Such regimes need to be individualized based on the drug sensitivity pattern of the source case isolate of drug-resistant TB. Thus, strategies for managing latent MDR-TB are the need of the day.</p> |
|---|---|
| DOI: | 10.17352/aprc.000063 |